ODOlivia Domanski

Olivia Domanski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Olivia Domanski has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Magalie Ladouceur

    Department of Congenital Heart Diseases, Hôpital Marie Lannelongue , 14 Avenue Galilée, 92350 Le Plessis-Robinson

    2 shared publications
  • Sébastien Hascoët

    Congenital Heart Diseases, M3C Rare Diseases Network, Hôpital Marie‑Lannelongue, France

    2 shared publications
  • Alexandre Delarue

    Service de Cardiologie infantile et congénitale CHU de Lille Lille France

    1 shared publication
  • Alexis Hermida

    UR4666 HEMATIM, équipe CARDIOMICS, Centre Universitaire de Recherche en Santé Université de Picardie Jules Verne Amiens France

    1 shared publication
  • Ali Houeijeh

    Department of Pediatric and Congenital Heart Disease, University of Lille-Nord de France, France

    1 shared publication
  • Anissa Boubrit

    Adult Congenital Heart Disease Unit Hôpital Européen Georges Pompidou Centre de Référence des Malformations Cardiaques Congénitales Complexes Assistance Publique‐Hôpitaux de Paris Paris University Paris France

    1 shared publication

Latest Publications

  • Open Access

    Thromboprophylaxis in congenital and acquired heart disease across the lifespan. A French consensus position statement: Part 2 – from adolescence to adulthood

    by Clement Karsenty, Magalie Ladouceur, Neil Derridj, Olivia Domanski, Estiballiz Valdeolmillos, Pamela Moceri, Dominique Lasne, Nicolas Combes, Ramona Ghenghea, Laurence Iserin, et al.

  • Open Access

    Genetic Architecture of Pediatric Cardiomyopathies Assessed by Whole‐Exome Sequencing: Insights Into Early‐Onset and Syndromic Forms

    by Luana Giovannangeli, Elise Daire, Kahia Messaoudi, Didier Herent, Nathalie Desjeux, Emilie Lacot‐Leriche, Sarah Sauval, Sabine Dirani, Pascal De Groote, Didier Klug, et al.

    Pediatric cardiomyopathies (CM) are rare and heterogeneous heart disorders, including hypertrophic, dilated, restrictive, arrhythmogenic, and non‐dilated CM. While their genetic basis is well characterized in adults, it remains less clearly defined in children particularly in early‐onset apparently isolated and syndromic forms. We conducted a retrospective study (2018–2024) of 59 pediatric patients who underwent Whole‐Exome Sequencing (WES) for CM at Amiens and Lille University Hospitals, aiming to characterize the genetic architecture of pediatric CM. WES identified at least one Variant Of Interest (VOI) in 62.7% of patients (37/59), including 45.8% (27/59) of P/LP variants, and 16.9% (10/59) of VUS. VOI identification yields for HCM and DCM were respectively 67.7% and 57.1%. Yield was higher in patients diagnosed before 1 year of age compared with those diagnosed later (72.7% vs. 56.7%). Variants were identified in classical CM genes, including sarcomeric genes, but also in less typical and syndromic genes. Among patients diagnosed before 6 months, 55% carried a variant in genes associated with syndromic cardiomyopathy, including cases with initially isolated cardiac phenotypes. These findings support the use of WES as a first‐line approach in pediatric CM and highlight the contribution of complex and syndromic genetic architectures to early‐onset and severe diseases.


  • Open Access

    Health‐Related Quality of Life and Its Association With Outcomes in Adults With Congenital Heart Disease and Heart Failure: Insight From FRESH‐ACHD Registry

    by Reaksmei Ly, Clément Karsenty, Pascal Amedro, Sarah Cohen, Olivia Domanski, Francois Godart, Jelena Radojevic, Guy Vaksmann, Nicole Naccache, Anissa Boubrit, et al.

    Background: Quality of Life (QoL) is a prognostic factor in heart failure (HF) of patients with acquired cardiac disease. The aim of this study was to determine the predictive value of QoL on outcomes in adults with congenital heart disease (ACHD) and HF. Methods and Results: Quality of life of 196 adults with congenital heart disease with clinical heart failure (HF) (mean age: 44.3±13.8 years; 51% male; 56% with complex congenital heart disease; 47% New York Heart Association class III/IV) included in the prospective multicentric registry FRESH‐ACHD (French Survey on Heart Failure−Adult with Congenital Heart Disease) was assessed using the 36‐Item Short Form Survey (SF‐36), a patient‐reported survey. The primary end point was defined by all‐cause death, HF‐related hospitalization, heart transplantation, and mechanical circulatory support. At 12 months, 28 (14%) patients reached the combined end point. Patients with low quality of life experienced major adverse events more frequently (logrank P =0.013). On univariate analysis, lower score at physical functioning (hazard ratio [HR], 0.98 [95% CI, 0.97–0.99]; P =0.008), role limitations related to physical health (HR, 0.98 [95% CI, 0.97–0.99]; P =0.008), and general health dimensions of the SF‐36 (HR, 0.97 [95% CI, 0.95–0.99]; P =0.002) were significantly predictive of cardiovascular events. However, after multivariable analysis, SF‐36 dimensions were no longer significantly associated with the primary end point. Conclusions: Patients with congenital heart disease with HF and poor quality of life experience severe events more frequently, making quality of life assessment and rehabilitation programs essential to alter their trajectory.


  • Top Cited Papers
    Open Access

    Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib

    by Gabriel Morin, Caroline Degrugillier-Chopinet, Marie Vincent, Antoine Fraissenon, Hélène Aubert, Célia Chapelle, Clément Hoguin, François Dubos, Benoit Catteau, Florence Petit, et al.

    PIK3CA-related overgrowth spectrum (PROS) includes rare genetic conditions due to gain-of-function mutations in the PIK3CA gene. There is no approved medical therapy for patients with PROS, and alpelisib, an approved PIK3CA inhibitor in oncology, showed promising results in preclinical models and in patients. Here, we report for the first time the outcome of two infants with PROS having life-threatening conditions treated with alpelisib (25 mg) and monitored with pharmacokinetics. Patient 1 was an 8-mo-old girl with voluminous vascular malformation. Patient 2 was a 9-mo-old boy presenting with asymmetrical body overgrowth and right hemimegalencephaly with West syndrome. After 12 mo of follow-up, alpelisib treatment was associated with improvement in signs and symptoms, morphological lesions and vascular anomalies in the two patients. No adverse events were reported during the study. In this case series, pharmacological inhibition of PIK3CA with low-dose alpelisib was feasible and associated with clinical improvements, including a smaller size of associated complex tissue malformations and good tolerability.


  • Is the new Occlutech duct occluder an appropriate device for transcatheter closure of patent ductus arteriosus?

    by François Godart, Ali Houeijeh, Olivia Domanski, Marie-Paule Guillaume, Mélanie Brard, Hugues Lucron


  • Open Access

    An unexpected rise in cardiac troponin I in a patient with multiple myeloma

    by Olivia Domanski, Sylvestre Maréchaux, Gerard Forzy, Jean-Michel Lemahieu